|
|
|
|
| LEADER |
01287nam a2200241 u 4500 |
| 001 |
EB002191786 |
| 003 |
EBX01000000000000001329251 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Erenumab (Aimovig) (Novartis pharmaceuticals Canada Inc.)
|h Elektronische Ressource
|b indication: for prevention of migraine in patients who have had at least four migraine days monthly
|
| 246 |
3 |
1 |
|a Erenumab (Aimovig) (Novartis pharmaceuticals Canada Inc.)
|
| 246 |
3 |
1 |
|a Clinical review report for erenumab (Aimovig)
|
| 250 |
|
|
|a Version: Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 2020, 2020
|
| 300 |
|
|
|a 1 PDF file (163 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK566776
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month
|